IL-17 in systemic lupus erythematosus

José C Crispín, George C Tsokos, José C Crispín, George C Tsokos

Abstract

IL-17 is a cytokine with powerful proinflammatory activity. Production of IL-17 is abnormally increased in patients with systemic lupus erythematosus (SLE), a multiorgan chronic autoimmune disease. In patients with SLE, CD3+CD4(-)CD8(-) (double negative) T cells are an important source of IL-17. IL-17 produced by double negative and CD4 T cells participates in the pathogenesis of the disease. IL-17-producing T cells are present in the kidneys of patients with lupus nephritis. IL-17 increased production in patients with SLE can amplify the immune response by increasing target organ inflammation and damage and by augmenting the production of antibodies by B cells.

Figures

Figure 1
Figure 1
The IL-17 response is amplified in SLE. Nucleic acid-containing immune complexes and other inflammatory stimuli (e.g., cytokines) induce the production of pro-inflammatory cytokines by dendritic cells. These factors, along with others not yet identified, favor the generation of pro-inflammatory IL-17-producing T cell subsets (i.e., TH17 and DN T cells) able to migrate to target organs and inflict damage. Produced IL-17 amplifies the inflammatory response and stimulates other cell types (e.g., B cells).

References

    1. Crispín JC, Liossis S-NC, Kis-Toth K, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends in Molecular Medicine. 2010;16(2):47–57.
    1. Rouvier E, Luciani M-F, Mattei M-G, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus Saimiri gene. The Journal of Immunology. 1993;150(12):5445–5456.
    1. Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nature Reviews Immunology. 2009;9(12):883–889.
    1. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. Journal of Leukocyte Biology. 2002;71(1):1–8.
    1. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annual Review of Immunology. 2007;25:821–852.
    1. Toy D, Kugler D, Wolfson M, et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. The Journal of Immunology. 2006;177(1):36–39.
    1. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annual Review of Immunology. 2009;27:485–517.
    1. Peck A, Mellins ED. Precarious balance: Th17 cells in host defense. Infection and Immunity. 2010;78(1):32–38.
    1. Woltman AM, de Haij S, Boonstra JG, Gobin SJP, Daha MR, van Kooten C. Interleukin-17 and CD40-Ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. Journal of the American Society of Nephrology. 2000;11(11):2044–2055.
    1. Witowski J, Pawlaczyk K, Breborowicz A, et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GROα chemokine from mesothelial cells. The Journal of Immunology. 2000;165(10):5814–5821.
    1. Ruddy MJ, Shen F, Smith JB, Sharma A, Gaffen SL. Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment. Journal of Leukocyte Biology. 2004;76(1):135–144.
    1. Laan M, Cui Z-H, Hoshino H, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. The Journal of Immunology. 1999;162(4):2347–2352.
    1. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-γ and TNF-α. The Journal of Immunology. 1999;162(1):494–502.
    1. Schwarzenberger P, Huang W, Ye P, et al. Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. The Journal of Immunology. 2000;164(9):4783–4789.
    1. Cai X-Y, Gommoll CP, Jr., Justice L, Narula SK, Fine JS. Regulation of granulocyte colony-stimulating factor gene expression by interleukin-17. Immunology Letters. 1998;62(1):51–58.
    1. Ruddy MJ, Wong GC, Liu XK, et al. Functional cooperation between interleukin-17 and tumor necrosis factor-α is mediated by CCAAT/enhancer-binding protein family members. Journal of Biological Chemistry. 2004;279(4):2559–2567.
    1. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis and Rheumatism. 2003;48(3):594–601.
    1. Van Bezooijen RL, Farih-Sips HCM, Papapoulos SE, Lowik CW. Interleukin-17: a new bone acting cytokine in vitro. Journal of Bone and Mineral Research. 1999;14(9):1513–1521.
    1. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis: genetics and immunobiology. Current Gastroenterology Reports. 2008;10(6):568–575.
    1. Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis and Rheumatism. 2000;43(11):2455–2463.
    1. Crispin JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. The Journal of Immunology. 2008;181(12):8761–8766.
    1. Wong CK, Lit LCW, Tam LS, Li EKM, Wong PTY, Lam CWK. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clinical Immunology. 2008;127(3):385–393.
    1. Wong CK, Ho CY, Li EK, Lam CWK. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus. 2000;9(8):589–593.
    1. Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nature Immunology. 2009;10(7):778–785.
    1. Yang J, Chu Y, Yang X, et al. Th17 and natural treg cell population dynamics in systemic lupus erythematosus. Arthritis and Rheumatism. 2009;60(5):1472–1483.
    1. Crispin JC, Tsokos GC. Human TCR-αβ+CD4−CD8− T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. The Journal of Immunology. 2009;183(7):4675–4681.
    1. Wang Y, Ito S, Chino Y, et al. Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clinical and Experimental Immunology. 2010;159(1):1–10.
    1. Dong G, Ye R, Shi W, et al. IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chinese Medical Journal. 2003;116(4):543–548.
    1. Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis. The Journal of Immunology. 2009;183(5):3160–3169.
    1. Wang Y, Ito S, Chino Y, et al. Use of laser microdissection in the analysis of renal-infiltrating T cells in MRL/lpr mice. Modern Rheumatology. 2008;18(4):385–393.
    1. Kang H-K, Liu M, Datta SK. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. The Journal of Immunology. 2007;178(12):7849–7858.
    1. Wu HY, Quintana FJ, Weiner HL. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ The Journal of Immunology. 2008;181:6038–6050.
    1. Hsu H-C, Zhou T, Kim H, et al. Production of a novel class of polyreactive pathogenic autoantibodies in BXD2 mice causes glomerulonephritis and arthritis. Arthritis and Rheumatism. 2006;54(1):343–355.
    1. Hsu H-C, Yang PA, Wang J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nature Immunology. 2008;9(2):166–175.
    1. Hsu H-C, Wu Y, Yang P, et al. Overexpression of activation-induced cytidine deaminase in B cells is associated with production of highly pathogenic autoantibodies. The Journal of Immunology. 2007;178(8):5357–5365.
    1. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179–189.
    1. Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-β are required for differentiation of human TH17 cells. Nature. 2008;454:350–352.
    1. Mangan PR, Harrington LE, O’Quinn DB, et al. Transforming growth factor-β induces development of the TH17 lineage. Nature. 2006;441:231–234.
    1. Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. Journal of Clinical Investigation. 1982;69(6):1388–1392.
    1. Stockinger B. Good for goose, but not for gander: IL-2 interferes with Th17 differentiation. Immunity. 2007;26(3):278–279.
    1. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235–238.
    1. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. The Journal of Immunology. 1991;147(1):117–123.
    1. Wong CK, Wong PTY, Tam LS, Li EK, Chen DP, Lam CWK. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. Journal of Clinical Immunology. 2010;30(1):45–52.
    1. Yu CF, Peng WM, Oldenburg J, et al. Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. The Journal of Immunology. 2010;184(3):1159–1167.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe